Since NF-κB activation is responsible for the progressive suppression of apoptosis affecting differentiation of MDS cells and contribute to malignant transformation [11], proteasome inhibitors may be effective in the treatment of high-risk MDS. This evidence concerns the gene NFKB1 and myelodysplastic syndrome.